Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019
June 21, 2019 07:30 ET
|
Iterum Therapeutics plc
Limited options remain for successful empiric treatment of uncomplicated urinary tract infections (uUTIs) in the community DUBLIN, Ireland and CHICAGO, June 21, 2019 (GLOBE NEWSWIRE) -- Iterum...
Iterum Therapeutics Reports First Quarter 2019 Financial Results
May 14, 2019 07:00 ET
|
Iterum Therapeutics plc
On track to complete enrollment in all three Phase 3 clinical trials before year-end Filed patent application that may extend Iterum’s intellectual property rights into the 2040s DUBLIN,...
Iterum Therapeutics Presents Data on Risks for Treatment Failure Associated with Uncomplicated Urinary Tract Infection and Activity of its Novel Antibiotic Sulopenem at ECCMID 2019
April 11, 2019 07:30 ET
|
Iterum Therapeutics plc
The highest risk of treatment failure is seen in patients previously infected with a resistant pathogen. Sulopenem has in vitro activity against isolates of Neisseria gonorrhoeae non-susceptible to...
Iterum Therapeutics Receives QIDP for Oral and IV Sulopenem in Four Additional Indications as well as Fast Track Designation
March 19, 2019 07:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Iterum to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
February 19, 2019 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
October 05, 2018 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Iterum to Present at Cantor Fitzgerald Global Healthcare Conference
September 25, 2018 16:05 ET
|
Iterum Therapeutics plc
DUBLIN and CHICAGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens,...
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
September 18, 2018 08:00 ET
|
Iterum Therapeutics plc
Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product candidate sulopenem Potential to be first and only oral and IV penem antibiotic available...
Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights
August 14, 2018 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
August 09, 2018 16:05 ET
|
Iterum Therapeutics plc
First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over...